#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Parkinson's disease Myotonic dystrophy Thyroid cancer metastatic Osteosarcoma recurrent Arterial disorder Primary hyperoxaluria Follicular lymphoma Uterine leiomyosarcoma Ischaemic stroke Acute lymphocytic leukaemia Alpha-1 antitrypsin deficiency Colorectal adenocarcinoma Chronic lymphocytic leukaemia refractory Nodal marginal zone B-cell lymphoma Methylmalonic acidaemia More trials…

    Learn about Rare Diseases

    Angiosarcoma recurrent – Life with Disease Urea cycle disorder – Trials in Disease Soft tissue sarcoma – Life with Disease Activated PI3 kinase delta syndrome – Diagnostics IgA nephropathy – Basic Information Choroid melanoma – Trials in Disease Rhabdoid tumour Hereditary hypophosphataemic rickets – Diagnostics Brain stem glioma – Life with Disease Medulloblastoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tiragolumab Immunoglobulin G Ecubectedin Triptorelin Pamoate Obefazimod Ipatasertib Olopatadine Hydrochloride Metformin Embonate Riluzole Camizestrant CHLOROQUINE PHOSPHATE Oxygen TEDUGLUTIDE LUNRESERTIB Danicamtiv Brepocitinib Tosilate Dalteparin Sodium Ab-1002 Pristinamycin Dexamethasone Acetate More therapies…

    Learn about Your Condition

    Cutaneous T-cell lymphoma Hypoalbuminaemia Measles Orthostatic hypotension Uterine leiomyosarcoma Viral infection Pulmonary venous thrombosis Pneumococcal infection Synovial sarcoma recurrent White matter lesion Brain injury Peritoneal dialysis Malignant oligodendroglioma Myositis KBG syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Laiko General Hospital Of Athens

Laiko General Hospital Of Athens

Messogion Avenue 152, Athens, 115 27, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

    Recruiting

    2 1
    Investigated Diseases:
    • Acute kidney injury
    Belgium Czechia Denmark France Germany Greece +3

  • Study comparing firmonertinib with osimertinib or afatinib for patients with advanced lung cancer with uncommon EGFR mutations

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Afatinib
    • N-[2-[2-(Dimethylamino)Ethyl-Methylamino]-5-[[4-(1-Methylindol-3-Yl)Pyrimidin-2-Yl]Amino]-6-(2,2,2-Trifluoroethoxy)Pyridin-3-Yl]Prop-2-Enamide
    • Osimertinib
    France Greece Italy Spain

  • A study to evaluate the safety of dazodalibep in patients with Sjögren’s Syndrome over a long period of time

    Recruiting

    3 1 1
    Investigated Drugs:
    • Dazodalibep
    Belgium Croatia Denmark France Germany Greece +6

  • Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ranibizumab
    Austria Belgium Bulgaria Croatia Czechia France +7

  • Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Buclizine Hydrochloride
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia France Germany Greece +7

  • A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +10

  • A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9

  • A study testing duvakitug for patients with moderately to severely active ulcerative colitis

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9

  • A Study of Autologous Urothelial Cell Treatment with Bioprinter During Bladder Reconstruction Surgery in Patients with Muscle-Invasive Bladder Cancer

    Recruiting

    1 1 1
    Investigated Drugs:
    • AUROCELL-TX
    Greece

  • Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

    Recruiting

    3 1
    Investigated Drugs:
    • ZILEBESIRAN
    Austria Belgium Bulgaria Czechia Denmark France +11
Previous Page
1 … 3 4 5 6 7 … 38
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!